Top

Cancer Causes & Control

Published in:

01-12-2010 | Original paper

Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland

Authors: K. Korhonen, J. Raitanen, J. Isola, H. Haapasalo, T. Salminen, A. Auvinen

Published in: Cancer Causes & Control | Issue 12/2010

Abstract

Background

Previous studies on association of exogenous female sex hormones and risk for meningioma have yielded conflicting results. The aim of this study was to evaluate the potential relation between prior use of menopausal hormone therapy or oral contraception and risk of meningioma.

Methods

This population-based case–control study was conducted during years 2000–2002 in Finland. All women aged 20–69 years with meningioma diagnosis were identified from five university hospitals, and frequency-matched controls were randomly chosen from population register. A total of 264 cases and 505 controls were interviewed on their use of menopausal hormone therapy, oral and other contraception, fertility treatment, treatment for gynecological problems, age at menarche, and number of children. We also analyzed separately tumors expressing progesterone or estrogen receptors. Of the successfully stained tumor specimens, 86.3% were positive for progesterone receptor and 50% for estrogen receptor.

Results

Postmenopausal hormonal treatment, use of contraceptives, or fertility treatment did not influence the risk of meningioma. In further analysis by hormone receptor status, there was some indication for an increased risk of progesterone receptor-positive meningiomas associated with oral contraceptive use (OR 1.39, 95% confidence interval 0.92–2.10) and other hormonal contraception (OR 1.50, 95% CI 0.95–2.36).

Conclusions

Overall, we found little indication that reproductive factors or use of exogenous sex hormones affect meningioma risk.

Vernooij MW, Lkram MA, Tanghe HL et al (2007) Incidental findings on brain MRI in the general population. N Engl J Med 357(18):1812–1818CrossRef

Klaeboe L, Lonn S, Scheie D et al (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway, and Sweden 1968–1997. Int J Cancer 117(6):996–1001CrossRefPubMed

Krampla W, Newrkla S, Pfisterer W et al (2004) Frequency and risk factors for meningioma in clinically healthy 75-year-old patients. Cancer 100(6):1208–1212CrossRefPubMed

Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ (2004) Radiation-induced meningiomas: clinical, pathological, and cytogenetic characteristics. J Neurosurg 100(6):1002–1013CrossRefPubMed

Phillips LE, Frankenfeld C, Drangsholt M, Koespell TD, van Belle G, Longstreth WT (2005) Intracranial meningioma and ionizing radiation in medical and occupational settings. Neurology 64(2):350–352PubMed

Preston-Martin S, Pogoda JM, Schlehofer B et al (1998) An international case-control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 27(4):579–585CrossRefPubMed

Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J (1992) Medical risk factors and the development of brain tumors. Cancer 69(10):2541–2547CrossRefPubMed

Schlehofer B, Blettner M, Preston-Martin S et al (1999) Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 82(2):155–160CrossRefPubMed

Schwartzbaum J, Jonsson F, Ahlbom A et al. (2005) Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomark Prev 14(3):643–650

10.

Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD (2008) Occupational exposure to pesticides and risk of adult brain tumors. Am J Epidemiol 167(8):976–985CrossRefPubMed

11.

Navas-Acien A, Pollan M, Gustavsson P, Plato N (2002) Occupation, exposure to chemicals and risk of gliomas and meningiomas in Sweden. Am J Ind Med 42(3):214–227CrossRefPubMed

12.

Schüz J, Böhler E, Berg G et al (2006) Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epidemiol 163(6):12–20CrossRef

13.

Hsu DW, Efird JT, Headley-White ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113–120CrossRefPubMed

14.

Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7CrossRefPubMed

15.

Rubinstein AB, Loven D, Geier A, Reichental E, Gadoth N (1994) Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 81(2):184–187CrossRefPubMed

16.

Hatiboglu MA, Cosar M, Iplikcioglu C, Ozcan D (2008) Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol 69(4):356–362CrossRefPubMed

17.

Roelvink NC, Kamphorst W, August H, van Alphen HAM, Rao BR (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44(2):209–215PubMed

18.

Custer BS, Koepsell T, Mueller BA (2002) The association of breast carcinoma and meningioma in women. Cancer 94(6):1626–1635CrossRefPubMed

19.

Schoenberg BS, Christine BW, Wisnant JP (1975) Nervous system neoplasms and primary malignances of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712PubMed

20.

Grunberg SM, Weiss MH, Russell CA et al (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727–733CrossRefPubMed

21.

Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unrespectable or refractory meningiomas: a Southwest Oncology Group Study. J Neurooncol 15:75–77CrossRefPubMed

22.

Hatch EE, Linet M, Zhang J et al (2005) Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 114(5):797–805CrossRefPubMed

23.

Lambe M, Coogan P, Baron J (1997) Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 72(3):389–393CrossRefPubMed

24.

Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119(5):1152–1157CrossRefPubMed

25.

Benson VS, Pirie K, Green J et al. (2010) Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Int J Cancer 127(7):1692–1698

26.

Custer B, Longstreth W, Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152CrossRefPubMed

27.

Jhawar BS, Fuchs C, Golditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99(5):848–853CrossRefPubMed

28.

Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M, Swedish INTERPHONE Study Group (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636

29.

Preston-Martin S, Monroe K, Lee P et al (1995) Spinal meningiomas in women in Los Angeles County: investigation of an etiological hypothesis. Cancer Epidemiol Biomarkers Prev 4(4):333–339PubMed

30.

Blitshteyn S, Crook J, Jaeckle KE (2008) Is there an association between meningioma and hormone replacement therapy. J Clin Oncol 26(2):279–282CrossRefPubMed

31.

Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188(11):641–644PubMed

32.

Hersh AL, Stefanick M, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47–53CrossRefPubMed

33.

Cardis E, Richardson L, Deltour I et al (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 22(9):647–664CrossRefPubMed

34.

Lyytinen H, Pukkala E, Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108(6):1354–1360CrossRefPubMed

35.

Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847CrossRefPubMed

36.

Rexhepaj E, Brennan DJ, Holloway P et al (2008) Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 10(5):R89CrossRefPubMed

37.

Benson VS, Piric K, Green J, Casabonne D, Beral V (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 99(1):185–190CrossRefPubMed

38.

Schlehofer B, Blettner M, Wahrendorf J (1992) Association between brain tumors and menopausal status. J Natl Cancer Inst 84(17):1346–1349CrossRefPubMed

39.

Lahkola A, Salminen T, Auvinen A (2005) Selection bias due to differential participation in a case-control study of mobile phone use and brain tumours. Ann Epidemiol 15(5):321–325CrossRefPubMed

40.

Koponen P, Luoto K (ed) (2004) Reproductive health in Finland. The health 2000 survey. Publication of the National Public Health Institute B5, Helsinki

41.

Larjavaara S, Haapasalo H, Sankila R, Helen P, Auvinen A (2008) Is the incidence of meningiomas underestimated? A regional survey study. Br J Cancer 99(1):182–184CrossRefPubMed

Title: Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland
Authors: K. Korhonen
J. Raitanen
J. Isola
H. Haapasalo
T. Salminen
A. Auvinen
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9634-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2010

Models for local implementation of comprehensive cancer control: meeting local cancer control needs through community collaboration

Australian women’s awareness of ovarian cancer symptoms, risk and protective factors, and estimates of own risk

Nighttime light level co-distributes with breast cancer incidence worldwide

Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women

Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis

Breast cancer screening interventions in selected counties across US regions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer